Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0HESHM |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Hu1084 |
|||||
| Organization | Division of Developmental Therapeutics, EPOC, National Cancer Center, Kashiwa, Japan. |
|||||
| Synonyms |
Hu1084
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized lgG |
|||||
| Antigen Name | Undisclosed |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
hu1084-MMAE-DAR8 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.07۪.00 nM
|
High TF expression (TF +++) | ||
| Method Description |
Pancreatic cancer cell lines HPAF-II, BxPC-3, or PSN-1 were harvested on 96-well plates (Corning) and incubated at 37°C overnight. Payloads and ADCs were applied to each well at various concentrations, and the plates were incubated at 37°C for 6 days (n = 3). Cancer cell viability was measured using CCK-8 (Dojindo).
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | HPAF-II cells | CVCL_0313 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.18۪.02 nM
|
Moderate TF expression (TF++) | ||
| Method Description |
Pancreatic cancer cell lines HPAF-II, BxPC-3, or PSN-1 were harvested on 96-well plates (Corning) and incubated at 37°C overnight. Payloads and ADCs were applied to each well at various concentrations, and the plates were incubated at 37°C for 6 days (n = 3). Cancer cell viability was measured using CCK-8 (Dojindo).
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.65۪.01 nM
|
Low TF expression (TF+) | ||
| Method Description |
Pancreatic cancer cell lines HPAF-II, BxPC-3, or PSN-1 were harvested on 96-well plates (Corning) and incubated at 37°C overnight. Payloads and ADCs were applied to each well at various concentrations, and the plates were incubated at 37°C for 6 days (n = 3). Cancer cell viability was measured using CCK-8 (Dojindo).
|
||||
| In Vitro Model | Pancreatic adenocarcinoma | PSN-1 cells | CVCL_1644 | ||
hu1084-MMAE-DAR3 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.08۪.00 nM
|
High TF expression (TF +++) | ||
| Method Description |
Pancreatic cancer cell lines HPAF-II, BxPC-3, or PSN-1 were harvested on 96-well plates (Corning) and incubated at 37°C overnight. Payloads and ADCs were applied to each well at various concentrations, and the plates were incubated at 37°C for 6 days (n = 3). Cancer cell viability was measured using CCK-8 (Dojindo).
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | HPAF-II cells | CVCL_0313 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.09۪.00 nM
|
Moderate TF expression (TF++) | ||
| Method Description |
Pancreatic cancer cell lines HPAF-II, BxPC-3, or PSN-1 were harvested on 96-well plates (Corning) and incubated at 37°C overnight. Payloads and ADCs were applied to each well at various concentrations, and the plates were incubated at 37°C for 6 days (n = 3). Cancer cell viability was measured using CCK-8 (Dojindo).
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
2.12۪.18 nM
|
Low TF expression (TF+) | ||
| Method Description |
Pancreatic cancer cell lines HPAF-II, BxPC-3, or PSN-1 were harvested on 96-well plates (Corning) and incubated at 37°C overnight. Payloads and ADCs were applied to each well at various concentrations, and the plates were incubated at 37°C for 6 days (n = 3). Cancer cell viability was measured using CCK-8 (Dojindo).
|
||||
| In Vitro Model | Pancreatic adenocarcinoma | PSN-1 cells | CVCL_1644 | ||
hu1084-DXd-DAR8 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.54۪.02 nM
|
Moderate TF expression (TF++) | ||
| Method Description |
Pancreatic cancer cell lines HPAF-II, BxPC-3, or PSN-1 were harvested on 96-well plates (Corning) and incubated at 37°C overnight. Payloads and ADCs were applied to each well at various concentrations, and the plates were incubated at 37°C for 6 days (n = 3). Cancer cell viability was measured using CCK-8 (Dojindo).
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
1.39۪.47 nM
|
High TF expression (TF +++) | ||
| Method Description |
Pancreatic cancer cell lines HPAF-II, BxPC-3, or PSN-1 were harvested on 96-well plates (Corning) and incubated at 37°C overnight. Payloads and ADCs were applied to each well at various concentrations, and the plates were incubated at 37°C for 6 days (n = 3). Cancer cell viability was measured using CCK-8 (Dojindo).
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | HPAF-II cells | CVCL_0313 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 100 nM | Low TF expression (TF+) | ||
| Method Description |
Pancreatic cancer cell lines HPAF-II, BxPC-3, or PSN-1 were harvested on 96-well plates (Corning) and incubated at 37°C overnight. Payloads and ADCs were applied to each well at various concentrations, and the plates were incubated at 37°C for 6 days (n = 3). Cancer cell viability was measured using CCK-8 (Dojindo).
|
||||
| In Vitro Model | Pancreatic adenocarcinoma | PSN-1 cells | CVCL_1644 | ||
hu1084-DXd-DAR3 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.55۪.20 nM
|
Moderate TF expression (TF++) | ||
| Method Description |
Pancreatic cancer cell lines HPAF-II, BxPC-3, or PSN-1 were harvested on 96-well plates (Corning) and incubated at 37°C overnight. Payloads and ADCs were applied to each well at various concentrations, and the plates were incubated at 37°C for 6 days (n = 3). Cancer cell viability was measured using CCK-8 (Dojindo).
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
2.09۪.29 nM
|
High TF expression (TF +++) | ||
| Method Description |
Pancreatic cancer cell lines HPAF-II, BxPC-3, or PSN-1 were harvested on 96-well plates (Corning) and incubated at 37°C overnight. Payloads and ADCs were applied to each well at various concentrations, and the plates were incubated at 37°C for 6 days (n = 3). Cancer cell viability was measured using CCK-8 (Dojindo).
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | HPAF-II cells | CVCL_0313 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 100 nM | Low TF expression (TF+) | ||
| Method Description |
Pancreatic cancer cell lines HPAF-II, BxPC-3, or PSN-1 were harvested on 96-well plates (Corning) and incubated at 37°C overnight. Payloads and ADCs were applied to each well at various concentrations, and the plates were incubated at 37°C for 6 days (n = 3). Cancer cell viability was measured using CCK-8 (Dojindo).
|
||||
| In Vitro Model | Pancreatic adenocarcinoma | PSN-1 cells | CVCL_1644 | ||
References